Dear Reader,
As we approach the end of 2016, and publish our final issue of Drugs—Real World Outcomes for the year, we wish to reflect on another successful year for the journal and for others in the Adis Premier journals portfolio, and to thank all who have contributed to Drugs—Real World Outcomes over the past 12 months.
Anzeige
An important milestone was reached for Drugs—Real World Outcomes in that the journal content is now available on PubMed Central. Another of our open access journals, Drug Safety—Case Reports, is also now available on PubMed Central.
As of September 2016, Drugs—Real World Outcomes’ top 10 downloaded articles from SpringerLink this year were:
-
Elliott, R.A., Lee, C.Y., Beanland, C. et al. Medicines Management, Medication Errors and Adverse Medication Events in Older People Referred to a Community Nursing Service: A Retrospective Observational Study. Drugs—Real World Outcomes (2016) 3: 13.
-
Kocis, P.T., Liu, G., Makenbaeva, D. et al. Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation. Drugs—Real World Outcomes (2016) 3: 165.
-
Mast, G., Fernandes, K., Tadrous, M. et al. Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study. Drugs—Real World Outcomes (2016) 3: 175.
-
Lajara, R., Nikkel, C. & Abbott, S. The Clinical and Economic Impact of the V-Go® Disposable Insulin Delivery Device for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk. Drugs—Real World Outcomes (2016) 3: 191.
-
Watras, M.M., Patel, J.P. & Arya, R. Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants? A Review of the Literature. Drugs—Real World Outcomes (2016) 3: 1.
-
Mold, J.W. & Holtzclaw, B.J. Selective Serotonin Reuptake Inhibitors and Night Sweats in a Primary Care Population. Drugs—Real World Outcomes (2015) 2: 29.
-
Aggarwal, N. Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors. Drugs—Real World Outcomes (2016) 3: 145.
-
Rojas-Fernandez, C.H. Can 5-HT3 Antagonists Really Contribute to Serotonin Toxicity? A Call for Clarity and Pharmacological Law and Order. Drugs—Real World Outcomes (2014) 1: 3.
-
Muduma, G., Odeyemi, I. & Pollock, R.F. Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice. Drugs—Real World Outcomes (2016) 3: 61.
-
de Jong, J., Garne, E., de Jong-van den Berg, L.T.W. et al. The Risk of Specific Congenital Anomalies in Relation to Newer Antiepileptic Drugs: A Literature Review. Drugs—Real World Outcomes (2016) 3: 131.
We offer our sincere thanks to all authors who have contributed articles to Drugs—Real World Outcomes over the course of 2016. Their skill and dedication are critical to the continued publication of the journal. The quality of published articles is, similarly, testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal’s content is held to the highest possible standard. We would like to thank the following individuals who acted as reviewers for Drugs—Real World Outcomes in the last 12 months:
Anzeige
Adebowale Dele Ademola, Nigeria
Kraemer Alwin, Germany
Richard H. Aster, USA
Pierrick Bedouch, France
Nancy Bernardy, USA
Benoit Boland, Belgium
Machaon Bonafede, USA
Neil Brickel, UK
Anzeige
Marta Brooks, USA
Anette Bygum, Denmark
Johanna Callhoff, Germany
Wendy Cheng, USA
Anzeige
Victoria Collings, UK
Rohan A. Elliott, Australia
Barbara Farrell, Canada
Paula Fresco, Portugal
Anzeige
Masahiro M. Fukuoka, Japan
Chris Gillette, USA
B. Joseph Guglielmo, USA
Zeky Yüksel Gunaydin, Turkey
Mark Haggard, UK
Jesper Hallas, Denmark
Mainul Haque, Malaysia
Swapnil Hiremath, Canada
Keith B. Hoffman, USA
Chun-Ta Huang, Taiwan
Klejda Hudhra, Spain
Sekwon Jang, USA
Susan Jick, USA
Pravin Kamble, USA
Harparkash Kaur, UK
Donald G. Klepser, USA
Paul T. Kocis, USA
Sam Kosari, Australia
Richard Laing, USA
Cecilie Johannessen Landmark, Norway
Marianne Lisby, Denmark
Eleanor Lucas, USA
Hendrika Luijendijk, The Netherlands
Anke H. Maitland-van der Zee, The Netherlands
Louise Mallet, Canada
G. B. John Mancini, Canada
Gloria Manso, Spain
John F. McCarthy, USA
Natalie McCormick, Canada
Anthony B. Miller, Canada
Andrew Mosholder, USA
Domenico Motola, Italy
Marco Mula, UK
Giorgio Mustacchi, Italy
Paul N. Newton, UK
Onyema Ogbuagu, USA
Jan Palmblad, Sweden
Jean-Jacques Parienti, France
Timo Partonen, Finland
Kathryn Peri, New Zealand
Sathirakorn Pongpanich, Thailand
Valentin Prieto-Centurion, USA
Neal Ready, USA
Jenna M. Reps, UK
John Robst, USA
Albert Roger, Spain
Josea Rono, Kenya
Sabine Ruths, Norway
Alan Schorr, USA
Todd Semla, USA
Pasquale Striano, Italy
Roger E. Thomas, Canada
Philippe Thuillier, France
Petra A. Thurmann, Germany
James E. Tisdale, USA
Giuliano Tocci, Italy
Antonella Tosti, USA
Robert Vander Stichele, Belgium
Bastiaan Venhuis, The Netherlands
Pa-Chun Wang, Taiwan
Juanita Westbury, Australia
Peter K.K. Wong, Australia
Antoinette A. Wozniak, USA
In addition, we would like to thank the members of the journal’s Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:
G.C. Alexander, Johns Hopkins University, Baltimore, MD, USA
A. Beresniak, Data Mining International, Geneva, Switzerland
M.L. Berger, Pfizer, Inc., New York, NY, USA
H. Birnbaum, Analysis Group, Inc., Boston, MA, USA
J.M. Bottomley, Amygdala Ltd., Letchworth Garden City, England
P. Denig, University of Groningen, Groningen, The Netherlands
J.E. Fincham, Presbyterian College School of Pharmacy, Clinton, SC, USA
B. Godman, Karolinska Institutet, Stockholm, Sweden
D. Goldsmith, Goldsmith Pharmacovigilance and Systems, New York, NY, USA
S. Karve, AstraZeneca, Gaithersburg, MD, USA
N.Y. Kirson, Analysis Group, Inc., Boston, MA, USA
C. Kozma, CK Consulting Associates, St. Helena Island, SC, USA
T. Lasky, MIE Resources, Baltimore, MD, USA
A.A. Mangoni, Flinders University, Adelaide, SA, Australia
S. Mimica-Matanovic, University Hospital Osijek, Osijek, Croatia
A. Modi, Merck, Whitehouse Station, NJ, USA
J.K. Sluggett, Monash University, Parkville, VIC, Australia
K.A. Swanson, University of Oklahoma, Oklahoma City, OK, USA
J.E Ware Jr., University of Massachusetts, Worcester, MA, USA
Q. Zou, The Lewin Group, Falls Church, VA, USA
In other portfolio news, mid-2016 saw the release of the ISI Journal Citation Reports and the latest journal impact factors. The majority of our journals saw a rise in impact factor against the previous year. Most notably, five of our journals saw an increase of over 10% in impact factor – The Patient (17.08%), Clinical Drug Investigation (15.99%), the American Journal of Clinical Dermatology (13.17%), Drug Safety (13.5%), and Drugs (12.43%).
The Adis journals portfolio will expand in 2017, with the launch of PharmacoEconomics—Open. This new journal will be fully open access and will focus on the publication of applied research on the economic implications and health outcomes associated with drugs, devices and other healthcare interventions. It joins our other well respected health outcomes publications, PharmacoEconomics, Applied Health Economics and Health Policy, and The Patient: Patient-Centered Outcomes Research.
We hope that you have found the articles published throughout 2016 to be both interesting and informative. We have appreciated the high quality of content contributed to the journal this year and look forward to keeping you up to date with topical real-world outcomes in 2017.
With best wishes from Dene Peters (Editor-in-Chief) and Kathy Fraser (Deputy Editor).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.